(NASDAQ: RXST) Rxsight's forecast annual revenue growth rate of 32.26% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.18%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Rxsight's revenue in 2024 is $89,077,000.On average, 4 Wall Street analysts forecast RXST's revenue for 2024 to be $4,874,072,179, with the lowest RXST revenue forecast at $4,863,863,614, and the highest RXST revenue forecast at $4,884,465,683. On average, 4 Wall Street analysts forecast RXST's revenue for 2025 to be $6,449,594,115, with the lowest RXST revenue forecast at $6,186,538,617, and the highest RXST revenue forecast at $6,724,337,681.
In 2026, RXST is forecast to generate $7,460,574,983 in revenue, with the lowest revenue forecast at $7,253,629,607 and the highest revenue forecast at $7,667,520,359.